Professor Georgina Long makes history as the first woman and first Australian to lead the Society for Melanoma Research
26 October 2018
In a double world-first, Co-Medical Director of Melanoma Institute Australia, Professor Georgina Long, is the first woman and the first Australian to be President of the prestigious Society for Melanoma Research (SMR).
Professor Long has been inducted as SMR President at the 15th International Congress of the Society for Melanoma Research in Manchester, England.
Her election as President is testament to her international standing as one of the world’ pre-eminent melanoma clinicians and researchers, with her ground-breaking clinical trials tripling life expectancy for some advanced melanoma patients, and essentially curing others.
‘It is a great honour to represent and lead this prestigious research society,’ Professor Long said. ‘Its members are leaders in the field of cancer research, and it was this group of researchers that lead the penicillin moment in cancer-therapy with immune checkpoint inhibitors.
‘I am excited and humbled to receive the baton from Professor Keith Flaherty who has served as President for the last two years.’
Fellow Co-Medical Director of Melanoma Institute Australia, Professor Richard Scolyer, said the history-making accolade is well deserved.
‘Professor Long has changed the face of melanoma treatment around the world and many thousands of people are alive today thanks to her intellect, determination and passion,’ Professor Scolyer said.
‘To be the first Australian and the first woman elected as SMR President shows Professor Long’s stellar international reputation. It is thanks to her research and global thought leadership that the world is now realistically looking towards advanced melanoma one day becoming a chronic disease rather than a terminal one.’
Founded in 2004, the US-based Society for Melanoma Research is the world’s largest association of melanoma researchers and scientists. Its multidisciplinary approach promotes international collaboration aimed at facilitating innovative solutions to the challenges faced by melanoma clinicians and researchers across the globe.
Only three years ago, Professor Long was the recipient of the Young Investigators Award at SMR, presented to an independent researcher in the early stages of their career who has surpassed all expectations in their contributions to melanoma research.
Professor Long leads the clinical trials team and laboratory at MIA, with a focus on targeted therapy and immune-oncology in melanoma. She is Principal Investigator on Phase I, II and III trials in adjuvant and metastatic melanoma, and is the Chief Investigator on research funded by the NHMRC that looks at tissue biomarker correlates of systemic therapy sensitivity and resistance.
Professor Long has authored over 200 publications in melanoma clinical and translational research, including in high-impact journals such as the New England Journal of Medicine and The Lancet. She has presented at hundreds of international conferences.
In addition to her joint medical leadership of Melanoma Institute Australia, Professor Long is Chair of Melanoma Medical Oncology and Translational Research at Royal North Shore Hospital, The University of Sydney. She is also the medical oncology lead for the Australian Melanoma Management Guidelines Committee, is on the editorial boards of several high-impact journals, and is a member of the Melanoma Expert Panel for AJCC Cancer Staging System 8th edition.
Amongst her numerous awards include the prestigious Sir Zelman Cowen Universities Fund Prize for Discovery in Medical Research in 2016, and last year the translational research team led by Professors Long and Scolyer received the award for Excellence in Translational Cancer Research at the NSW Premier’s Awards for Outstanding Cancer Research.
‘Professor Long’s election as President of arguably the world’s most prestigious association fostering international collaboration between leading melanoma researchers and clinicians is a proud moment for us all here at Melanoma Institute Australia,’ said Matthew Browne, CEO.
‘Hardly a week goes by without a melanoma patient or their family expressing their gratitude for Professor Long’s ground-breaking research and clinical trials which have afforded them or their loved ones valuable extra time, and in many cases, a new chance at life.
‘She is a true role model for all young Australians, particularly young women, who may be working towards a career in science and medicine,’ he said.
Five years ago Julie Randall was diagnosed with melanoma and was given months to live. The melanoma had spread throughout her body. The doctors said it was incurable and she’d be lucky if she survived the next nine months. Julie, a patient at Melanoma Institute Australia under Professor Georgina Long was placed on an experimental drug trial. To watch the entire program, visit 9now.com or click here.
Meet our latest Surgical Oncology Fellow, Eva Nagy, to find out more about life as a surgical oncologist, why she came to MIA and what she hopes to achieve.
Melanoma research at ASCO this year focussed on the more precise use of current treatments to ensure optimal treatment for each patient.
MIA recently demonstrated that reflectance confocal microscopy is a useful tool in the clinic to diagnose suspicious-looking lesions in the mouth.
New research is likely to change the way melanoma is managed in many patients by reducing the need for major surgery and its associated morbidity and cost.
Researchers from MIA will present their latest research findings to the world’s largest oncology conference in early June.
Australian researchers pioneer life-extending treatment for advanced melanoma patients with brain tumours
Australian researchers are the first to demonstrate that patients with advanced melanoma which has spread to the brain can have increased life expectancy and possibly even beat the disease.
Melanoma March 2017 - that's a wrap! Thank you to everyone that helped make it happen.
Thank you so much to all those who contributed in a variety of ways to Melanoma March 2017 in 17 different locations and more around the country! You have contributed to getting the Big Data for Melanoma national Research Project happening!
By looking at the ‘dark matter’ of the genome, new research has found that genetic changes in acral and mucosal melanoma are completely different to mutations found in skin melanoma.
‘Slip, slop, slap’ is synonymous with being Australian and playing it safe in the sun. These sun smart rules reduce our chances of getting melanoma of the skin. However, new research tells a different story for those affected by rarer forms of melanoma.
Using MIA's patient database, researchers have developed conditional survival estimates for Stage III melanoma patients to more accurately predict survival outcomes.
MIA is proud to be celebrating an important milestone – the 60th anniversary of melanoma research and Australian-led global efforts to find a cure.
Research achievements by MIA were celebrated at the annual Sydney Medical School recently.
In this Global Research Report we showcase advances in medical oncology, reveal unexpected pathology in acral and skin melanoma, and uncover biomarkers and new gene targets for melanoma.
Professor’s Long and Scolyer are well known in the academic community and beloved by their patients. But we wanted to get to know our new Conjoint Medical Directors a little more and hear their plans on making an impact on melanoma.
Wyong Rugby League Club Group has joined forces with Melanoma Institute Australia to help end melanoma for future generations.
Melanoma research has reached a milestone with the 10,000th patient giving their permission for their blood and tissue samples to be used in the world’s largest melanoma biospecimen bank.
MIA's researchers and clinicians are in Seattle, USA, today sharing their research findings at the prestigious Society of Surgical Oncology’s Annual Cancer Symposium.